Dr. Jennifer Bath is the president and chief executive officer of ImmunoPrecise Antibodies LTD, an Austin, Texas based AI driven biotherapeutics company focused on accelerating the discovery of new therapeutics. Dr. Jennifer Bath leads corporate strategy, acquisitions, and the integration of international subsidiaries while guiding the development of proprietary technologies that support drug and vaccine research. Her academic background includes a PhD in cellular and molecular biology with a research focus on tropical diseases and vaccines, particularly those affecting children and vulnerable populations in developing regions. She has also served as an associate professor at Concordia College and worked as a principal investigator studying host cell response immunomodulation in helminth infections. Through leadership roles in biotechnology and global vaccine initiatives, her work connects scientific discovery with efforts to improve disease prevention and expand access to life saving immunizations worldwide.
Advancing Global Vaccines to Fight Neglected Diseases
Around the world, millions of people continue to suffer from neglected tropical diseases such as dengue, malaria, cholera, schistosomiasis, and leishmaniasis, all of which disproportionately affect communities in low-income and remote regions. These diseases cause significant illness, disability, and economic hardship. Vaccines play a critical role in changing this reality, offering one of the most effective tools for prevention, protection, and long-term disease control.
Developing vaccines for tropical diseases is a complex scientific challenge. Many of these pathogens are biologically diverse, mutate quickly, or have life cycles that make them difficult to target. Unlike diseases common in wealthier countries, neglected diseases often lack strong commercial incentives for research and development.
As a result, progress depends heavily on public funding, academic research, and partnerships between governments, nonprofits, and biotechnology companies. Advances in immunology, genomics, and manufacturing technologies have accelerated vaccine development in recent years, making it possible to design safer and more effective vaccines even for historically difficult targets.
Once a vaccine exists, delivering it to the people who need it most presents an entirely different set of challenges. Many affected populations live in rural or hard-to-reach areas with limited healthcare infrastructure. Poor roads, unreliable electricity, and shortages of trained healthcare workers can make routine immunization difficult. Maintaining cold-chain storage (keeping vaccines at safe temperatures from production to administration) is especially challenging in hot climates and remote regions. In addition, conflict and political instability can disrupt vaccination campaigns and reduce access to care.
Community engagement is another essential factor in successful vaccine delivery. In some regions, distrust of healthcare systems or cultural barriers can limit vaccine acceptance. Education and local partnerships are critical to building trust and ensuring that vaccination programs are understood and embraced. When communities are involved in planning and outreach, vaccination efforts are far more likely to succeed and achieve lasting impact.
Global health organizations play a central role in overcoming these barriers. Groups such as the World Health Organization coordinate international disease surveillance, establish vaccination guidelines, and support national immunization strategies. The Gavi, the Vaccine Alliance, helps finance vaccine development and distribution in low-income countries, ensuring that cost does not prevent access to life-saving immunizations. UNICEF supports vaccine procurement, logistics, and delivery, often managing supply chains in some of the world’s most challenging environments.
These collaborative efforts have already delivered meaningful results. Expanded vaccination campaigns have reduced deaths from diseases such as measles and yellow fever and have helped control outbreaks before they spread across borders. In some cases, vaccines are paired with other public health measures, such as improved sanitation, mosquito control, and access to clean water, creating a comprehensive approach to disease prevention. This integrated strategy not only protects individuals but also strengthens entire health systems.
The impact of global vaccination efforts extends beyond health outcomes. Preventing disease reduces healthcare costs, supports economic stability, and allows children to attend school and adults to remain productive. For communities burdened by neglected diseases, vaccines can break cycles of poverty and illness that persist across generations.
Vaccines are a powerful force in the fight against neglected tropical diseases, but their success depends on more than scientific breakthroughs alone. Effective delivery, community trust, and global collaboration are equally essential. Through continued investment, innovation, and international cooperation, global vaccination efforts are bringing hope to some of the world’s most vulnerable populations.
About Dr. Jennifer Bath
Dr. Jennifer Bath is the president and chief executive officer of ImmunoPrecise Antibodies LTD in Austin, Texas. She holds a PhD in cellular and molecular biology and conducted research on vaccines and tropical diseases that affect vulnerable populations. Her career includes leadership roles at Aldevron and CC Global Vaccine Institute. Dr. Jennifer Bath also serves as chairman of the board at BioStrand and has led acquisitions and global strategy initiatives across multiple biotechnology subsidiaries.
About The Author
